Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, placebo-controlled study to assess the safety and tolerability of PN-1094A after single and multiple ascending doses of PN-10943A in normal healthy volunteers

Trial Profile

A randomized, double-blind, placebo-controlled study to assess the safety and tolerability of PN-1094A after single and multiple ascending doses of PN-10943A in normal healthy volunteers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Jan 2019

At a glance

  • Drugs PN 10943A (Primary)
  • Indications Inflammatory bowel diseases; Ulcerative colitis
  • Focus Adverse reactions
  • Sponsors Protagonist Therapeutics
  • Most Recent Events

    • 13 Dec 2018 According to a Protagonist Therapeutics media release, the company announced initiation of dosing in the Phase 1 study and data will be used to design a Phase 2a study in ulcerative colitis.
    • 13 Dec 2018 Status changed from not yet recruiting to recruiting, according to a Protagonist Therapeutics media release.
    • 27 Nov 2018 According to a Protagonist Therapeutics media release, results are expected in the first half of 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top